Exploración de una variante de hirudina de sanguijuelas no hematófagas: desentrañando la secuencia completa, el splicing alternativo, la función y el potencial como nuevo polipéptido anticoagulante
Exploring a Hirudin variant from nonhematophagous leeches: Unraveling full-length sequence, alternative splicing, function, and potential as a novel anticoagulant polypeptide
Estudio de genómica funcional en la revista J Ethnopharmacol (2024)
Resumen
ETHNOPHARMACOLOGICAL RELEVANCE: Leeches exhibit robust anticoagulant activity, making them useful for treating cardiovascular diseases in traditional Chinese medicine. Whitmania pigra, the primary source species of leech-derived medicinal compounds in China, has been demonstrated to possess formidable anticoagulant properties. Hirudin-like peptides, recognized as potent thrombin inhibitors, are prevalent in hematophagous leeches. Considering that W. pigra is a nonhematophagic leech, the following question arises: does a hirudin variant exist in this species? AIM OF THE STUDY: In this study we identified the hirudin-encoding gene (WP_HV1) in the W. pigra genome. The goal of this study was to assess its anticoagulant activity and analyze the related mechanisms. MATERIALS AND METHODS: In this study, a hirudin-encoding gene, WP_HV1, was identified from the W. pigra genome, and its accurate coding sequence (CDS) was validated through cloning from cDNA extracted from fresh W. pigra specimens. The structure of WP_HV1 and the amino acids associated with its anticoagulant activity were determined by sequence and structural analysis and prediction of its binding energy to thrombin. E. coli was used for the expression of WP_HV1 and recombinant proteins with various structures and mutants. The anticoagulant activity of the synthesized recombinant proteins was then confirmed using thrombin time (TT). RESULTS: Validation of the WP_HV1 gene was accomplished, and three alternative splices were discovered. The TT of the blank sample exceeded that of the recombinant WP_HV1 sample by 1.74 times (0.05 mg/ml), indicating positive anticoagulant activity. The anticoagulant activity of WP_HV1 was found to be associated with its C-terminal tyrosine, along with the presence of 9 acidic amino acids on both the left and right sides. A significant reduction in the corresponding TT was observed for the mutated amino acids compared to those of the wild type, with decreases of 4.8, 6.6, and 3.9 s, respectively. In addition, the anticoagulant activity of WP_HV1 was enhanced and prolonged for 2.7 s when the lysine-67 residue was mutated to tryptophan. CONCLUSION: Only one hirudin-encoding variant was identified in W. pigra. The active amino acids associated with anticoagulation in WP_HV1 were resolved and validated, revealing a novel source for screening and developing new anticoagulant drugs.
Resumen tomado de PubMed (NCBI) para el registro citado, en el idioma original. La versión de referencia es la de la publicación original.
El resumen se deja sin traducir para conservar la redacción original de los autores.
Síntesis
En el genoma de Whitmania pigra se identificó el gen de hirudina WP_HV1, validado por clonación de cDNA, con tres splicings alternativos. El tiempo de trombina (TT) del blanco superó al de la muestra recombinante (0,05 mg/ml) en 1,74 veces, indicativo de actividad anticoagulante positiva. Las mutaciones acortaron el TT frente al tipo salvaje en 4,8, 6,6 y 3,9 s; la de lisina-67 a triptófano potenció la actividad 2,7 s. Solo se identificó una variante de hirudina.
Por qué esto importa para la hirudoterapia
Este estudio identificó y caracterizó un gen codificante de hirudina (WP_HV1) en el genoma de la sanguijuela no hematófaga Whitmania pigra. Mediante clonación y ensayos in vitro con proteínas recombinantes, los investigadores validaron su actividad anticoagulante y determinaron aminoácidos específicos cruciales para su función. Esta investigación es altamente relevante para el estudio farmacológico de moléculas derivadas de sanguijuela, al ofrecer nuevas dianas para el cribado y desarrollo de fármacos anticoagulantes. La limitación real es que se trata de un estudio de ciencia básica que depende por completo de clonación molecular y ensayos de coagulación in vitro, sin datos en animales ni clínicos.
Compuestos relacionados del registro de la ASH
Moléculas de la sanguijuela y fármacos derivados de la hirudina relacionados con el tema de este artículo, cada uno con un perfil completo en el registro de compuestos de la ASH:
Citación
Exploring a Hirudin variant from nonhematophagous leeches: Unraveling full-length sequence, alternative splicing, function, and potential as a novel anticoagulant polypeptide.
Yi X et al. · Journal of ethnopharmacology, 2024
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Investigación relacionada
Más estudios revisados por pares en la categoría «Genómica y proteómica».
- Leech Salivary Proteome and Transcriptome: 434 Deduced Protein Sequences — Liu Z, Tong X, Su Y, et al. (2019)
- Medicinal Leech Draft Genome — Anticoagulant Gene Survey — Kvist S, Manzano-Marín A, de Carle D, Trontelj P, Siddall ME (2020)
- Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
- Efficacy and Safety of Hirudotherapy for Improving Sperm Quality Parameters in Male Infertility: A Randomized Controlled Trial — Abtahi-Forooshani M et al. (2026)
- Hirudoterapia en la cicatrización de heridas — Nair H et al. (2022)
- Medicinal leeches and hirudotherapy — Gödekmerdan A et al. (2011)
- Cutaneous pseudolymphoma after hirudotherapy : Case report and review — Hanner S et al. (2022)
- Hirudoterapia en la presbiacusia precoz en liquidadores del accidente de Chernóbil durante los años posteriores a la catástrofe — Zabolotnyi D, Mishchanchuk N (2019)
- Hirudotherapy (medicinal leeches) for treatment of upper airway obstruction in a dog — Trenholme H, Masseau I, Reinero C (2021)
- Leech therapy — Yantis M, O'Toole K, Ring P (2009)
Añadido a la biblioteca ASH: 26 de mayo de 2026 · Última actualización del sitio: 18 de junio de 2026